Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M, Baselga J.

Science. 2019 Nov 8;366(6466):714-723. doi: 10.1126/science.aaw9032.

PMID:
31699932
2.

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN; GEICAM Spanish Breast Cancer Group; GBG (German Breast Group); Alliance for Clinical Trials in Oncology (Alliance).

Eur J Cancer. 2019 Aug;117:91-98. doi: 10.1016/j.ejca.2019.06.002. Epub 2019 Jul 2.

3.

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2019 Feb 15;25(4):1435. doi: 10.1158/1078-0432.CCR-18-4266. No abstract available.

4.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J.

Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008.

5.

A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.

Bao T, Seidman AD, Piulson L, Vertosick E, Chen X, Vickers AJ, Blinder VS, Zhi WI, Li Q, Vahdat LT, Dickler MN, Robson ME, Mao JJ.

Eur J Cancer. 2018 Sep;101:12-19. doi: 10.1016/j.ejca.2018.06.008. Epub 2018 Jul 13.

6.

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.

7.

Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.

Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A.

Breast Cancer Res Treat. 2018 Sep;171(2):325-334. doi: 10.1007/s10549-018-4828-5. Epub 2018 May 22.

8.

Checkpoint Inhibitors in the Treatment of Breast Cancer.

Lyons TG, Dickler MN, Comen EE.

Curr Oncol Rep. 2018 Apr 30;20(7):51. doi: 10.1007/s11912-018-0701-2. Review.

PMID:
29713831
9.

Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.

Scott JM, Iyengar NM, Nilsen TS, Michalski M, Thomas SM, Herndon J 2nd, Sasso J, Yu A, Chandarlapaty S, Dang CT, Comen EA, Dickler MN, Peppercorn JM, Jones LW.

Cancer. 2018 Jun 15;124(12):2552-2560. doi: 10.1002/cncr.31368. Epub 2018 Apr 6.

10.

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

Schleicher SM, Dickler MN.

Curr Breast Cancer Rep. 2017 Dec;9(4):236-241. doi: 10.1007/s12609-017-0260-9. Epub 2017 Oct 16.

11.

Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.

Brufsky AM, Dickler MN.

Oncologist. 2018 May;23(5):528-539. doi: 10.1634/theoncologist.2017-0423. Epub 2018 Jan 19. Review.

12.

Genetic predisposition to bevacizumab-induced hypertension.

Frey MK, Dao F, Olvera N, Konner JA, Dickler MN, Levine DA.

Gynecol Oncol. 2017 Dec;147(3):621-625. doi: 10.1016/j.ygyno.2017.09.017. Epub 2017 Sep 29.

PMID:
28969913
13.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. Erratum in: JAMA. 2018 Dec 11;320(22):2381.

14.

Sexual health needs and educational intervention preferences for women with cancer.

Stabile C, Goldfarb S, Baser RE, Goldfrank DJ, Abu-Rustum NR, Barakat RR, Dickler MN, Carter J.

Breast Cancer Res Treat. 2017 Aug;165(1):77-84. doi: 10.1007/s10549-017-4305-6. Epub 2017 May 25.

15.

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J.

Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5485.

16.

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J.

Science. 2017 Mar 24;355(6331):1324-1330. doi: 10.1126/science.aah6893. Erratum in: Science. 2019 Jan 25;363(6425):.

17.

18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2017 Jun 15;23(12):3053-3060. doi: 10.1158/1078-0432.CCR-16-2197. Epub 2016 Dec 23. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1435.

18.

Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.

Wen HY, Krystel-Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler MN, Norton L, Morrow M, Hudis CA, Brogi E.

Cancer. 2017 Jan 1;123(1):131-137. doi: 10.1002/cncr.30271. Epub 2016 Aug 15.

19.

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.

Murphy CG, Dickler MN.

Endocr Relat Cancer. 2016 Aug;23(8):R337-52. doi: 10.1530/ERC-16-0121. Epub 2016 Jul 12. Review.

PMID:
27406875
20.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ.

J Clin Oncol. 2016 Sep 1;34(25):3069-103. doi: 10.1200/JCO.2016.67.1487. Epub 2016 May 23.

PMID:
27217461
21.

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA.

J Clin Oncol. 2016 Aug 1;34(22):2602-9. doi: 10.1200/JCO.2015.66.1595. Epub 2016 May 2.

22.

Cancer and Fertility Program Improves Patient Satisfaction With Information Received.

Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, Goodman KA, Margolies A, Matasar MJ, Noy A, Goldfarb SB.

J Clin Oncol. 2016 May 20;34(15):1780-6. doi: 10.1200/JCO.2015.64.5168. Epub 2016 Apr 4.

23.

Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.

Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME.

Cancer. 2016 Apr 15;122(8):1178-84. doi: 10.1002/cncr.29903. Epub 2016 Feb 9.

24.

Molecular Imaging of Biomarkers in Breast Cancer.

Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W.

J Nucl Med. 2016 Feb;57 Suppl 1:53S-9S. doi: 10.2967/jnumed.115.157909. Review.

25.

Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?

Conlon N, Ross DS, Howard J, Catalano JP, Dickler MN, Tan LK.

Breast J. 2015 Sep-Oct;21(5):514-9. doi: 10.1111/tbj.12445. Epub 2015 Aug 14.

27.

The Role of CDK4/6 Inhibition in Breast Cancer.

Murphy CG, Dickler MN.

Oncologist. 2015 May;20(5):483-90. doi: 10.1634/theoncologist.2014-0443. Epub 2015 Apr 15. Review.

28.

Cancer-related internet information communication between oncologists and patients with breast cancer: a qualitative study.

Shen MJ, Dyson RC, D'Agostino TA, Ostroff JS, Dickler MN, Heerdt AS, Bylund CL.

Psychooncology. 2015 Nov;24(11):1439-47. doi: 10.1002/pon.3752. Epub 2015 Jan 28.

29.

Endocrine therapy for advanced breast cancer.

Shah PD, Dickler MN.

Clin Adv Hematol Oncol. 2014 Apr;12(4):214-23. Review.

PMID:
25003351
30.

Alopecia with endocrine therapies in patients with cancer.

Saggar V, Wu S, Dickler MN, Lacouture ME.

Oncologist. 2013;18(10):1126-34. doi: 10.1634/theoncologist.2013-0193. Epub 2013 Sep 13.

31.

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.

Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN.

Breast Cancer Res Treat. 2013 Jul;140(2):331-9. doi: 10.1007/s10549-013-2632-9. Epub 2013 Jul 19.

PMID:
23868188
32.

Nonimmediate hypersensitivity reaction after trastuzumab infusion: a suspected drug-virus interaction.

Ferastraoaru DE, Dickler MN, Patel S, Fischer EA, Pulitzer MP, Myskowski PL, Jerschow E.

J Clin Oncol. 2013 Aug 20;31(24):e407-9. doi: 10.1200/JCO.2012.45.9958. Epub 2013 Jun 10. No abstract available.

PMID:
23752107
33.

In reply.

Rosen AC, Gavrilovic IT, Balagula Y, Ramaswamy V, Dickler MN, Dunkel IJ, Lacouture ME.

Oncologist. 2013;18(4):e18. doi: 10.1634/theoncologist.2012-0421. Epub 2013 Apr 10. No abstract available.

34.

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.

Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS.

Clin Cancer Res. 2013 Mar 1;19(5):1281-9. doi: 10.1158/1078-0432.CCR-12-3029. Epub 2013 Jan 22.

35.

Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.

King V, Goldfarb SB, Brooks JD, Sung JS, Nulsen BF, Jozefara JE, Pike MC, Dickler MN, Morris EA.

Radiology. 2012 Sep;264(3):670-8. doi: 10.1148/radiol.12112669. Epub 2012 Jul 6.

PMID:
22771878
36.

Characteristics of oral mucosal events related to bevacizumab treatment.

Gavrilovic IT, Balagula Y, Rosen AC, Ramaswamy V, Dickler MN, Dunkel IJ, Lacouture ME.

Oncologist. 2012;17(2):274-8. doi: 10.1634/theoncologist.2011-0198. Epub 2012 Jan 26.

37.

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.

Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN.

Breast Cancer Res Treat. 2012 Jul;134(1):13-20. doi: 10.1007/s10549-011-1918-z. Epub 2011 Dec 24.

38.

Targeting the insulin-like growth factor pathway in estrogen receptor-positive breast cancer: a bumpy start with an uncertain future.

Dickler MN.

J Clin Oncol. 2011 Oct 10;29(29):3846-8. doi: 10.1200/JCO.2011.36.6393. Epub 2011 Sep 12. No abstract available.

PMID:
21911731
39.

Bevacizumab in metastatic breast cancer: when may it be used?

Goldfarb SB, Hudis C, Dickler MN.

Ther Adv Med Oncol. 2011 Mar;3(2):85-93. doi: 10.1177/1758834010397627.

40.

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN.

Clin Cancer Res. 2011 May 15;17(10):3398-407. doi: 10.1158/1078-0432.CCR-10-1969. Epub 2011 Feb 24.

41.

Updates on therapeutic approaches in HER2-positive disease.

Dickler MN.

Clin Adv Hematol Oncol. 2010 Feb;8(2):105-7. No abstract available.

PMID:
20386531
42.

Bevacizumab for advanced breast cancer.

Goldfarb SB, Traina TA, Dickler MN.

Womens Health (Lond). 2010 Jan;6(1):17-25. doi: 10.2217/whe.09.71. Review.

PMID:
20001867
43.

Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.

Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN.

J Clin Oncol. 2010 Feb 1;28(4):628-33. doi: 10.1200/JCO.2009.21.8784. Epub 2009 Oct 19.

44.

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.

Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA.

JAMA. 2009 Aug 19;302(7):774-80. doi: 10.1001/jama.2009.1204.

45.

Aromatase inhibitors and arthralgia: a growing pain?

Murphy C, Hudis CA, Dickler MN.

Oncology (Williston Park). 2008 Nov 15;22(12):1424, 1426. No abstract available.

46.

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.

Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA.

Clin Cancer Res. 2008 Dec 1;14(23):7878-83. doi: 10.1158/1078-0432.CCR-08-0141.

47.

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.

Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP.

Breast Cancer Res Treat. 2009 May;115(1):115-21. doi: 10.1007/s10549-008-0055-9. Epub 2008 May 22.

PMID:
18496750
48.

Biomarkers in breast cancer.

McArthur HL, Dickler MN.

Cancer Biol Ther. 2008 Jan;7(1):21-2. Epub 2008 Feb 11. No abstract available.

PMID:
18347421
49.

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.

Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN.

Breast Cancer Res Treat. 2008 Sep;111(2):377-88. Epub 2007 Oct 20.

PMID:
17952589
50.

When you look matters: the effect of assessment schedule on progression-free survival.

Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D.

J Natl Cancer Inst. 2007 Mar 21;99(6):428-32.

PMID:
17374832

Supplemental Content

Loading ...
Support Center